Biotech Industry · global
Northway Opens €61 Million Facility in Vilnius to Expand Cell Therapy Contract Manufacturing
When a batch of medicine may be made for just one patient, the key factors determining capacity change as well. Northway has added up to 20 independent production lines in Lithuania to meet development and manufacturing needs for personalized therapies, but its actual supply capacity remains undisclosed.
For some cell therapies, a single manufacturing run may serve just one patient. This broadens the challenge facing pharmaceutical plants from how to produce at scale to how to handle different cells simultaneously while safeguarding the identity and quality of each product. In September 2026, Northway Biotech announced the opening of its €61 million Cell Therapy and Personalized Medicine Center in Vilnius, Lithuania’s capital, adding another contract development and manufacturing organization (CDMO) option for these therapies.
Located in BIO CITY III, the new center covers 3,500 square meters and is designed to accommodate up to 20 independent production lines compliant with current Good Manufacturing Practice (cGMP). According to the company, the facility includes quality control laboratories, cleanrooms and segregated manufacturing areas, allowing multiple cell products and processes to run in parallel while maintaining product traceability and contamination control. The production line figure represents the facility’s maximum configuration; the company did not disclose how many lines are currently in production.
Services cover autologous therapies, which use patients’ own cells, and allogeneic therapies, which use donor cells, as well as personalized therapeutic vaccines, regenerative medicine and three-dimensional human tissue technologies. Northway said tissue models can be used to study drug effects and tissue repair. These areas encompass research, development and manufacturing applications and cannot all be regarded as treatments already available for patient use.
At its opening, the center had already secured its first customers and contracts for the development and manufacturing of advanced therapies, serving biotechnology and pharmaceutical companies, university hospitals and research institutions. The park’s operator, Northtown Vilnius, also confirmed this progress and noted that construction took more than a year. However, currently available public information does not identify customers, contract values or the clinical stages of the products, making it difficult to estimate the scale of orders or capacity utilization.
Within Northway’s existing operations, BIO CITY I handles biologic drug development and manufacturing, BIO CITY II provides gene therapy capabilities, and the newly added BIO CITY III brings cell therapy and personalized medicine capabilities. Nordic Life Science described the expansion as new capacity nearby that the Nordic biotech industry can choose to use. The new facility is operated by Kamieninių ląstelių tyrimų centras under the Northway Biotech brand and is expected to bring together approximately 100 life science professionals. Funding comes from private investment and loans from Lithuania’s national development bank, ILTE.
The opening gives cell therapy developers another specialized manufacturing site, but the facility’s scale alone does not answer questions about delivery speed, cost and batch quality. The announcement did not provide manufacturing success rates, output per batch or the regulatory progress of individual products. Further operating data will be needed to show how much actual supply capacity this investment can deliver.